{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:06:43Z","timestamp":1791166003426,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our study aimed to: 1)investigate the diagnostic utility of CSF A\u03b242, t-tau, and p-tau to differentiate normal-pressure-hydrocephalus(NPH) from Alzheimer\u2019s-disease(AD) and normal-controls; and 2)investigate if age and ventricular size affect the levels of CSF biomarkers in NPH patients. We recruited 131 participants: (a)Suspected-NPH: 72 with ventriculomegaly and clinical symptoms of NPH. These participants were then divided into two groups of 1)Probable-NPH (N\u2009=\u200938) and 2)Unlikely-NPH (N\u2009=\u200934) based on whether participants experienced gait improvement after removal of a large amount of CSF; (b)AD group: 30 participants with CSF biomarkers and cognitive symptoms consistent with AD; (c)Control-group: 29 participants who were cognitively and functionally normal. Lower levels of CSF A\u03b242 and p-tau were observed in the probable-NPH compared to the normal controls(444.22\u2009\u00b1\u2009163.3 vs. 1213.75\u2009\u00b1\u2009556.5; and 26.05\u2009\u00b1\u20099.2 vs. 46.16\u2009\u00b1\u200913.3\u2009pg\/mL; respectively). Lower levels of CSF p-tau and t-tau were found in the probable-NPH compared to the AD(26.05\u2009\u00b1\u20099.2 vs. 114.95\u2009\u00b1\u200928.2; and 193.29\u2009\u00b1\u200992.3 vs. 822.65\u2009\u00b1\u2009311.5\u2009pg\/mL; respectively) but the CSF-A\u03b242 was low in both the probable-NPH and AD. CSF-A\u03b242 correlated with age and Evans-index only in the probable-NPH(r\u2009=\u20090.460, p\u2009=\u20090.004; and r\u2009=\u2009\u22120.530, p\u2009=\u20090.001; respectively). Our study supports the hypothesis that age-related atrophy results in better A\u03b242 clearance in the CSF because of the increase in the interstitial space.<\/jats:p>","DOI":"10.1038\/s41598-020-66154-y","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T10:03:02Z","timestamp":1591264982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Association Between Cerebrospinal Fluid Biomarkers and Age-related Brain Changes in Patients with Normal Pressure Hydrocephalus"],"prefix":"10.1038","volume":"10","author":[{"given":"Foad","family":"Taghdiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musleh","family":"Algarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tang-Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"66154_CR1","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.0b013e31828c2fda","volume":"80","author":"A Jeppsson","year":"2013","unstructured":"Jeppsson, A., Zetterberg, H., Blennow, K. & Wikkels\u00f8, C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology 80, 1385\u20131392 (2013).","journal-title":"Neurology"},{"key":"66154_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1468-1331.2006.01593.x","volume":"14","author":"E Kapaki","year":"2007","unstructured":"Kapaki, E. et al. Cerebrospinal fluid tau, phospho\u2010tau181 and \u03b2\u2010amyloid1\u2212 42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer\u2019s disease. European journal of neurology 14, 168\u2013173 (2007).","journal-title":"European journal of neurology"},{"key":"66154_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1600-0404.2007.00890.x","volume":"116","author":"A \u00c5gren\u2010Wilsson","year":"2007","unstructured":"\u00c5gren\u2010Wilsson, A. et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta neurologica Scandinavica 116, 333\u2013339 (2007).","journal-title":"Acta neurologica Scandinavica"},{"key":"66154_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/WNL.0000000000000916","volume":"83","author":"NR Graff-Radford","year":"2014","unstructured":"Graff-Radford, N. R. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology 83, 1573\u20131575 (2014).","journal-title":"Neurology"},{"key":"66154_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","volume":"342","author":"L Xie","year":"2013","unstructured":"Xie, L. et al. Sleep drives metabolite clearance from the adult brain. science 342, 373\u2013377 (2013).","journal-title":"science"},{"key":"66154_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1227\/01.NEU.0000168185.29659.C5","volume":"57","author":"N Relkin","year":"2005","unstructured":"Relkin, N., Marmarou, A., Klinge, P., Bergsneider, M. & Black, P. M. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 57, S2\u20134 (2005).","journal-title":"Neurosurgery"},{"key":"66154_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1212\/WNL.26.3.231","volume":"26","author":"V Synek","year":"1976","unstructured":"Synek, V., Reuben, J. & Du Boulay, G. Comparing Evans\u2019 index and computerized axial tomography in assessing relationship of ventricular size to brain size. Neurology 26, 231\u2013231 (1976).","journal-title":"Neurology"},{"key":"66154_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0404.1994.tb02640.x","volume":"89","author":"T Sand","year":"1994","unstructured":"Sand, T. et al. Idiopathic normal pressure hydrocephalus: the CSF tap\u2010test may predict the clinical response to shunting. Acta neurologica scandinavica 89, 311\u2013316 (1994).","journal-title":"Acta neurologica scandinavica"},{"key":"66154_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease. NeuroRx 1, 213\u2013225 (2004).","journal-title":"NeuroRx"},{"key":"66154_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow, K. et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 11, 58\u201369 (2015).","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"66154_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53, 695\u2013699 (2005).","journal-title":"Journal of the American Geriatrics Society"},{"key":"66154_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-018-0382-y","volume":"10","author":"M Freedman","year":"2018","unstructured":"Freedman, M. et al. The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment. Alzheimer\u2019s research & therapy 10, 65 (2018).","journal-title":"Alzheimer\u2019s research & therapy"},{"key":"66154_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack Jr","year":"2008","unstructured":"Jack, C. R. Jr et al. The Alzheimer\u2019s disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine 27, 685\u2013691 (2008).","journal-title":"Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine"},{"key":"66154_CR14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert, F. et al. Improved discrimination of AD patients using \u03b2-amyloid (1\u221242) and tau levels in CSF. Neurology 52, 1555\u20131555 (1999).","journal-title":"Neurology"},{"key":"66154_CR15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/archneur.60.9.1202","volume":"60","author":"A Maddalena","year":"2003","unstructured":"Maddalena, A. et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to \u03b2-amyloid peptide42. Archives of neurology 60, 1202\u20131206 (2003).","journal-title":"Archives of neurology"},{"key":"66154_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1227\/NEU.0b013e318208f5e0","volume":"68","author":"AK Toma","year":"2011","unstructured":"Toma, A. K., Holl, E., Kitchen, N. D. & Watkins, L. D. Evans\u2019 index revisited: the need for an alternative in normal pressure hydrocephalus. Neurosurgery 68, 939\u2013944 (2011).","journal-title":"Neurosurgery"},{"key":"66154_CR17","unstructured":"Team, R. C. R: A Language and Environment for Statistical Computing. (2018)."},{"key":"66154_CR18","first-page":"22","volume":"2","author":"MC Shingala","year":"2015","unstructured":"Shingala, M. C. & Rajyaguru, A. Comparison of post hoc tests for unequal variance. International Journal of New Technologies in Science and Engineering 2, 22\u201333 (2015).","journal-title":"International Journal of New Technologies in Science and Engineering"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66154-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:02:45Z","timestamp":1670328165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66154-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66154"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66154-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F Taghdiri reports no disclosures. M Gumus reports no disclosures. M Algarni reports no disclosures. D Tang-Wai reports no disclosures. MC Tartaglia reports no disclosures. A Fasano received honoraria for consultancies from Abbvie, Abbott, BrainLab, Boston Scientific, Chiesi farmaceutici, Ipsen, Medtronic, Sunovion, and UCB; honaria for participation in advisory boards from Abbvie, Boston Scientific, and Ipsen; research grants from Abbvie, Boston Scientific, Cummings Foundation, Dystonia Medical Research Foundation Canada, Michael J. Fox Foundation, Medtronic, University of Toronto, and Weston foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9106"}}